As more employers stop covering GLP‑1 weight‑loss drugs like Wegovy and Zepbound, Americans are turning to direct‑to‑consumer (DTC) prescription programs. Big retailers, Walmart, Costco, CVS, and Amazon, are seizing this opportunity to expand their share of the pharmacy market.
These prescriptions aren’t just one‑time sales; they create ongoing customer relationships. Every refill brings shoppers back into stores or onto platforms, often leading them to buy other items. As one healthcare consultant put it, retailers see GLP‑1 programs as “the front door to obesity care,” opening the door to long‑term loyalty.
Pricing strategies reinforce this. Walmart, Costco, and Amazon are offering monthly programs starting as low as $25, while others use tiered discounts tied to refill schedules or memberships.
For example, Costco’s partnership with Sesame prices Wegovy at $349 but requires a $65 membership, effectively turning prescriptions into a way to sell memberships.
Walmart has bundled GLP‑1 prescriptions with nutrition coaching and fitness apps through its Better Care Services platform, aiming to be a one‑stop health destination. Amazon, meanwhile, leverages its One Medical acquisition and Amazon Pharmacy to provide low‑cost prescriptions with same‑day delivery in thousands of cities.
Independent pharmacies, however, are struggling. Owners say they can’t match the scale, pricing, or integrated services of the big chains, leaving patients at risk of fragmented care and missed drug‑interaction checks.
Experts warn that while cheaper access is appealing, focusing only on price risks overlooking broader healthcare needs. GLP‑1 drugs work best when paired with professional medical support, not just as stand‑alone prescriptions.
